I’m also curious to get your thoughts on The Journal’s Livongo’s plans for an initial public offering. Will we see other digital health companies (some unicorns, even) follow suit and get into the public market? Could get pretty interesting.
To kick a busy week off, I actually wanted to go back to last Friday evening, when insurance filings for 2018 went online.
We spared you the trouble and expense of combing through health insurance startups Oscar Health and Clover Health’s filings (more companies ahead! Still missing some filings…) to get to the good stuff.
On Monday, diabetes drugmaker Eli Lilly announced its plans to make an “authorized generic” version of Humalog that carries a list price of roughly half the branded version at $137 a vial. It’s a big move from the drugmaker in the hopes to make insulin more affordable at a time when many are struggling with high out of pocket costs for the lifesaving drug.
I spoke to Laura Marston, who has been living with type 1 diabetes for decades. She remembers what it was like to pay that exact price back in 2012. I also got some insight into why Lilly chose to go the authorized generic route, and why the company picked that particular price tag.
And in diabetes-related news, Emma Court spoke to folks who use Dexcom’s continuous glucose monitors about how the company’s plans to lay off 13% of its work force might affect Dexcom’s customer service.
Then Tuesday afternoon, we got the word that Gottlieb is leaving his post as FDA commissioner. Emma wrote up what it could mean for the e-cigarette and tobacco companies Gottlieb and the agency had taken on over the past two years.
Erin Brodwin‘s got some killer reporting this week about how Juul plans to market to smokers and the implications of that as well as a f act-check on the risks associated with vaping.
Later on Tuesday, the FDA (which was presumably having quite a busy day!) approved Johnson & Johnson’s depression drug esketamine, which will go by the brand name of Spravato.
Elsewhere, Emma took a look at the impact new gene therapies could have on the health system from a price perspective.
Emma also combed through Roche and Spark Therapeutics’ filings to bring you this breakdown of how Spark over the course of a dramatic 10 weeks got Roche all the way up to a $4.8 billion bid for the gene therapy maker.
Tangential to gene therapies, Erin has the scoop on how lab-grown meat might also benefit from the gene-editing tool Crispr. Right now, it’s still in experimental stage.
On that note, and with likely way too much already to chew on, I’ll leave you to head into your weekends. But as you recover and digest all that happened this week, feel free to send any thoughts, tips, and dream picks to serve as Gottlieb’s replacement to me at [email protected] or the whole health team at [email protected]